On November 18, Bristol-Myers Squibb fell 3.02% in Regular Trading, trading at $61.0 per share, with turnover of $273 million.
The move followed continued market assessment of the company’s R&D reorganization, under which scientific and clinical teams will be combined into a unified end-to-end R&D organization effective January 1, led by current Chief Medical Officer Cristian Massacesi, while Chief Research Officer Robert Plenge is set to depart after the transition in March.
Recent pipeline developments provided context but did not remove execution scrutiny: interim phase 3 data released in October showed izalontamab brengitecan cut the risk of progression or death by 59% versus chemotherapy in previously treated advanced HR-positive, HER2-negative breast cancer, with median progression-free survival of 8.2 months versus 4.0 months. Separately, a partner disclosed on November 17 that Bristol-Myers Squibb made a second $250 million milestone payment tied to the Iza-Bren agreement, keeping investor focus on development spending and eventual returns.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments